Effects of the Selective Progesterone Receptor Modulator Asoprisnil on Uterine Artery Blood Flow, Ovarian Activity, and Clinical Symptoms in Patients with Uterine Leiomyomata Scheduled for Hysterectomy
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Introduction: Asoprisnil, a novel orally active selective progesterone receptor modulator, is being studied for the management of symptomatic uterine leiomyomata. The exact mechanism of action is not yet discerned. The primary objectives of this double-blind, randomized, placebo-controlled study included evaluation of the effect of asoprisnil on uterine artery blood flow. Furthermore, we assessed effects of asoprisnil on leiomyoma symptoms. Patients and Methods: Thirty-three premenopausal patients scheduled for hysterectomy due to symptomatic uterine leiomyomata were recruited in four centers and treated with 10 or 25 mg asoprisnil or placebo for 12 wk before surgery. At baseline and before hysterectomy, all patients underwent sonographic assessment to measure impedance to uterine artery blood flow, determined by resistance index and pulsatility index, as well as volumes of largest leiomyoma and uterus. In addition, patients recorded intensity and frequency of menstrual bleeding on a menstrual pictogram. Each asoprisnil treatment was compared with placebo. Results: The increased pulsatility index in both asoprisnil groups and the statistically significantly increased resistance index within the 25-mg asoprisnil group suggest a moderately decreased uterine artery blood flow. Analysis of menstrual pictogram scores showed a statistically significant larger decrease in frequency and intensity of bleeding for both asoprisnil groups compared with placebo. Bleeding was suppressed by asoprisnil 25mg in 91% of patients. Asoprisnil treatment was well tolerated when administered daily for a 12-wk period, and no serious adverse events occurred. Conclusion: Asoprisnil moderately reduced uterine artery blood flow. This effect may contribute in part to the clinical effects of asoprisnil.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spies, J. (2002) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(01)01702-1 · Cited by 647
Chwalisz, K., Perez, M. C., DeManno, D., Winkel, C., Schubert, G., & Elger, W. (2005) · Endocrine Reviews · doi:10.1210/er.2005-0001 · Cited by 310
Determination of total menstrual blood loss
Wyatt, K. M., Dimmock, P. W., Walker, T. J., & O’Brien, P. M. S. (2001) · Fertility and Sterility · doi:10.1016/s0015-0282(01)01847-7 · Cited by 173
Cited by
Progesterone Is Essential for Maintenance and Growth of Uterine Leiomyoma
Ishikawa, H., Ishi, K., Serna, V. A., Kakazu, R., Bulun, S. E., & Kurita, T. (2010) · Endocrinology · doi:10.1210/en.2009-1225 · Cited by 362
Role of nuclear progesterone receptor isoforms in uterine pathophysiology
Patel, B., Elguero, S., Thakore, S., Dahoud, W., Bedaiwy, M., & Mesiano, S. (2015) · Human Reproduction Update · doi:10.1093/humupd/dmu056 · Cited by 353
Selective Progesterone Receptor Modulators—Mechanisms and Therapeutic Utility
Islam, M. S., Afrin, S., Jones, S. I., & Segars, J. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa012 · Cited by 143
“Adverse events including hot flashes, nausea, vomiting, lethargy, anorexia, fatigue/tiredness, abdominal pain, and vaginal discharge were associated with mifepristone (126, 280, 285, 287, 326, 337, 355), asoprisnil (292, 293), UPA (103, 237, 238, 306, 308, 309), telapristone acetate (249), and vilaprisan (319).”
BackgroundInfluentialWilkens, J., Male, V., Ghazal, P., Forster, T., Gibson, D. A., Williams, A. R. W., Brito-Mutunayagam, S. L., Craigon, M., Lourenco, P., Cameron, I. T., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300958 · Cited by 101
Self-citationWhitaker, L. H. R., Murray, A. A., Matthews, R., Shaw, G., Williams, A. R. W., Saunders, P. T. K., & Critchley, H. O. D. (2017) · Human Reproduction · doi:10.1093/humrep/dew359 · Cited by 77
Self-citation
Metadata
- Authors
- Wilkens, J., Chwalisz, K., Han, C., Walker, J., Cameron, I. T., Ingamells, S., Lawrence, A. C., Lumsden, M. A., Hapangama, D., Williams, A. R. W., & Critchley, H. O. D.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2008-12-01
- Volume
- 93
- Issue
- 12
- Pages
- 4664-4671
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2098019331
- Cited by
- 101
- References
- 3
- FWCI
- 7.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.